<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Journal of Research in Applied and Basic Medical Sciences</title>
<title_fa></title_fa>
<short_title>Journal of Research in Applied and Basic Medical Sciences</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijrabms.umsu.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn></journal_id_issn>
<journal_id_issn_online>2717-0098</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.61882/rabms</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1399</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2020</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<volume>6</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa>Serum levels of IL-6, TNF-α, and YKL-40 in patients with stage I multiple myeloma</title_fa>
	<title>Serum levels of IL-6, TNF-α, and YKL-40 in patients with stage I multiple myeloma</title>
	<subject_fa>تخصصي</subject_fa>
	<subject>Special</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>orginal article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;strong&gt;&lt;em&gt;Background &amp; Aims&lt;/em&gt;&lt;/strong&gt;: Multiple myeloma (MM) is a type of plasma cell malformation accounting for 10% of the blood cancers with unknown ethiopathology. MM causes changes in inflammatory proteins. The aim of this study was to evaluate the serum levels of IL-6, TNF-&amp;alpha;, and YKL-40 in patients with stage I MM&lt;span dir=&quot;RTL&quot;&gt;.&lt;/span&gt;&lt;br&gt;
&lt;strong&gt;Materials &amp; Methods:&lt;/strong&gt; This case-control study was performed on 28 patients with stage I MM including 14 males and 14 females with mean age of 62.11 &amp;plusmn; 6.71 years and 40 individuals as controls including 20 males and 20 females with mean age of 60.25 &amp;plusmn; 4.81 years matched in both age and sex. Serum concentrations of inflammatory factors including IL-6, TNF-&amp;alpha; and YKL-40 were measured using the sandwich Enzyme Linked Immunosorbent Assay (ELISA) method and the data were analyzed using SPSS software.&lt;br&gt;
&lt;strong&gt;Results&lt;/strong&gt;: The serum levels of IL-6 in patients with stage I MM (7.42&amp;plusmn;5.89 pg/ml) were significantly higher compared to the control group (1.67&amp;plusmn;1.08 pg/ml); (p&lt; 0.0001). Also, the serum levels of YKL-40 in the patients (45.86 &amp;plusmn; 9.14 ng/ml) were significantly higher compared to the control group (35.87 &amp;plusmn; 11.2 ng/ml); (p &lt;0.0001). Also, the levels of TNF-&amp;alpha; (8.02&amp;plusmn;1.75 pg/ml) were slightly high compared to the control group (7.77 &amp;plusmn; 1.91 pg/ml); (p=0.419).&lt;br&gt;
&lt;strong&gt;Conclusion:&lt;/strong&gt; According to the results in MM, inflammatory proteins such as YKL-40 andIL-6 are the major growth factor of the myeloma cells and help their survival.</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Multiple myeloma, IL-6, TNF-α, YKL-40</keyword>
	<start_page>160</start_page>
	<end_page>166</end_page>
	<web_url>http://ijrabms.umsu.ac.ir/browse.php?a_code=A-10-101-13&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Zeinab</first_name>
	<middle_name></middle_name>
	<last_name>Esmaeilzadeh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>monavvar03@gmail.com</email>
	<code>1003194753284600874</code>
	<orcid>1003194753284600874</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Fatemeh</first_name>
	<middle_name></middle_name>
	<last_name>Kheradmand</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>kheradmand.f@umsu.ac.ir</email>
	<code>1003194753284600875</code>
	<orcid>1003194753284600875</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Yousef</first_name>
	<middle_name></middle_name>
	<last_name>Rasmi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>rasmiy@umsu.ac.ir</email>
	<code>1003194753284600876</code>
	<orcid>1003194753284600876</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Mohammad Hassan</first_name>
	<middle_name></middle_name>
	<last_name>Khadem-Ansari</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>mhansari1@gmail.com</email>
	<code>1003194753284600877</code>
	<orcid>1003194753284600877</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
